Highlights

  • Third quarter 2026 revenues were $5,513 million, and net income attributable to GE HealthCare was $615 million, or $1.36 diluted.
  • GE HealthCare agreed on October 5, 2026 to acquire SOFIE Biosciences for $945 million in cash, closing expected in 2027.
  • Management said it now expects full-year 2026 adjusted EPS of $4.95 to $5.05 and organic revenue growth of approximately 4%.
  • Cash, cash equivalents and restricted cash were $2,854 million at September 30, 2026, and total debt was $9,973 million.

GE HealthCare Technologies (NASDAQ:GEHC) shares were trading at USD 76.85 on October 28, 2026, up 8.06%, with a relative volume at time of 3.65. The healthcare solutions provider announced an agreement to acquire SOFIE Biosciences on October 5, 2026, and reported third quarter 2026 results with a raised full-year outlook on October 28, 2026.

GE HealthCare Technologies Inc. is a Delaware corporation with principal executive offices in Chicago, Illinois. It describes itself as a global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions. Following a change in the second quarter of 2026, it has three reportable segments: Advanced Imaging Solutions (AIS), Pharmaceutical Diagnostics (PDx) and Patient Care Solutions (PCS). On March 18, 2026, it acquired Intelerad, a medical imaging software company, for approximately $2,293 million in cash, net of cash acquired. Its fiscal year ends December 31.

Third Quarter 2026 Results

Total revenues for the third quarter ended September 30, 2026 were $5,513 million, compared with $5,143 million a year earlier, growing 7.2% as reported and 6.2% organically, a non-GAAP measure. Operating income was $805 million, compared with $653 million. Net income attributable to GE HealthCare was $615 million, compared with $446 million, and diluted earnings per share were $1.36, compared with $0.98.

Segment revenues were $3,873 million for AIS, $846 million for PDx and $793 million for PCS. Regional revenues were $2,672 million in USCAN, $1,354 million in EMEA, $586 million in the China region and $901 million in Rest of World. On a non-GAAP basis, adjusted EBIT was $913 million and adjusted net income was $608 million.

For the nine months, total revenues were $15,939 million, compared with $14,927 million. Net income attributable to GE HealthCare was $1,564 million, or $3.44 per diluted share, compared with $1,495 million, or $3.26.

Balance Sheet, Cash Flow and Capital

Cash, cash equivalents and restricted cash were $2,854 million at September 30, 2026. Total debt was $9,973 million, compared with $10,003 million at December 31, 2025. Cash from operating activities for the nine months was $1,365 million, compared with $937 million, and free cash flow, a non-GAAP measure, was $973 million, compared with $589 million.

Cash used for investing activities was $2,726 million and included purchases of businesses, net of cash acquired, of $2,293 million for Intelerad. Financing activities included $300 million for repurchases of common stock. GE HealthCare repurchased 4.7 million shares in the nine months and had $500 million available under its repurchase program at September 30, 2026.

Business Developments

On October 5, 2026, GE HealthCare announced an agreement to acquire SOFIE Biosciences, a U.S.-based contract manufacturing organization for PET radiopharmaceuticals, for $945 million in cash. The transaction is subject to customary closing conditions, including regulatory approvals.

On the call, management said SOFIE is expected to add approximately 1% to total company revenue on an annualized basis. It also said the company is evaluating strategic options for its Patient Care Solutions business, and announced that the PCS leader is leaving and Neil Sandy will become its chief executive officer.

2026 Outlook

On the call, management said it is raising several full-year 2026 metrics. It now expects organic revenue growth of approximately 4%, adjusted EBIT margin of 15.5% to 15.7%, and adjusted EPS of $4.95 to $5.05 per share. It expects free cash flow in excess of $1.6 billion and an adjusted effective tax rate of 20% to 21% for the full year.

Management also said it expects a foreign exchange tailwind to revenue of approximately 75 basis points.